Haite Biotechnology: Announcement of Resolutions of the Sixth Meeting of the Ninth Board of Directors
Securities code: 300683 Securities abbreviation: Haite Biotechnology Announcement number: 2025-051
Wuhan Haite Biopharmaceutical Co., Ltd.
Announcement of Resolutions of the Sixth Meeting of the Ninth Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
1. Convening of board of directors meetings
The sixth meeting of the ninth board of directors of Wuhan Haite Biopharmaceutical Co., Ltd. (hereinafter referred to as "Haite Bio" or the "Company") was held at 10:00 on December 29, 2025, in the company conference room of Haite Science and Technology Park in a combination of on-site and communication methods. The meeting notice was delivered by fax or email on December 23, 2025. The meeting was chaired by Mr. Chen Ya, the chairman of the board. Nine people were expected to attend this meeting, but actually there were 9 people (including Mr. Yang Tao, Ms. Yan Jie, Mr. Zhu Jiafeng, Mr. Ran Mingdong, Mr. Mao Zongfu, and Mr. Zhou Haibing attended the meeting by communication). The company's senior management also attended the meeting. This meeting complied with the relevant provisions of the Company Law and the Articles of Association.
2. Review status of board of directors meeting
After deliberation, the meeting reached the following resolutions:
(1) Consideration and approval of the “Proposal on the Election of Independent Directors”
In accordance with the "Company Law of the People's Republic of China (revised in 2023)", "Guidelines on the Articles of Association of Listed Companies (revised in 2025)", "Measures for the Management of Independent Directors of Listed Companies", "Shenzhen Stock Exchange Stock Listing Rules (revised in 2025)", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operations of GEM Listed Companies (2025) "Revised in 2016", "Working Rules of the Nomination Committee of the Board of Directors" and other relevant provisions, as recommended by the Nomination Committee of the Company's Board of Directors and reviewed by the Company's Board of Directors, the Company's Board of Directors nominated Mr. Zeng Junkai and Mr. Shi Xianwang as independent director candidates for the ninth session of the Company's Board of Directors, with a term of three years from the date of review and approval by the shareholders' meeting. In order to ensure the normal operation of the Board of Directors, before the new directors take office, the original directors will still faithfully and diligently perform their duties and responsibilities in accordance with laws, regulations, normative documents and the Articles of Association.
The directors attending the meeting voted on the above candidates one by one. The voting results are as follows:
- Elected Mr. Zeng Junkai as an independent director of the ninth session of the company’s board of directors
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. The number of affirmative votes accounts for 100% of the valid votes.
- Elected Mr. Shi Xianwang as an independent director of the ninth session of the company’s board of directors
Voting results: 9 votes in favor, 0 votes against, and 0 abstentions. The number of affirmative votes accounts for 100% of the valid votes. For details, please refer to the "Announcement on the Election of Independent Directors" disclosed by the company on the cninfo website (http://www.cninfo.com.cn).
This proposal has been reviewed and approved by the Nomination Committee of the Company's Board of Directors before being submitted to the Board of Directors for review. During the shareholders' meeting, a cumulative voting system will be used to vote on each candidate item by item.
(2) Consider and approve the "Proposal on Changing the Use of Part of the Raised Funds, Closing Some Raised Investment Projects and Permanently Replenishing Working Capital with the Surplus Raised Funds"
Based on the company's development needs and the actual use of raised funds, in order to further improve the liquidity and use efficiency of raised funds, meet the company's actual operating needs, and promote the company's overall development, the company plans to develop the "High-end API Production Base Phase I Project ( API&CDMO)" will be closed, and the remaining raised funds will be used to permanently replenish working capital. At the same time, it is planned to change the raised fund investment project "High-end API R&D Pilot Project" to the "National Class I New Drug Eprenamin New Indications Research Project", and the implementation entity will be changed from "Hanrui Pharmaceutical (Jingmen) Co., Ltd." to "Wuhan Haite Biopharmaceutical Co., Ltd."
For details, please refer to the "Announcement on Changing the Use of Part of the Raised Funds and Closing Some Raised Investment Projects and Using the Surplus Raised Funds to Permanently Replenish Working Capital" disclosed by the company on the cninfo.com (http://www.cninfo.com.cn).
This proposal has been reviewed and approved by the Audit Committee of the Company's Board of Directors before being submitted to the Board of Directors for review.
Voting results: 9 votes in favor; 0 votes against; 0 abstentions. The number of affirmative votes accounts for 100% of the valid votes.
(3) Consideration and adoption of the "Proposal on the Use of Idle Own Funds for Cash Management"
In order to improve the efficiency of the company's use of funds, and without affecting the company's normal operations and ensuring the safety of funds, the company plans to use idle self-owned funds of no more than RMB 600 million to purchase low-risk financial products with an investment period of no more than 12 months, high security and good liquidity. Within the above quota and validity period, the funds can be used on a rolling basis, with a period of use not exceeding 1 year.
For details, please refer to the "Announcement on the Use of Idle Own Funds for Cash Management" disclosed by the company on the Juchao Information Network (http://www.cninfo.com.cn).
This proposal has been reviewed and approved by the Audit Committee of the Company's Board of Directors before being submitted to the Board of Directors for review.
Voting results: 9 votes in favor; 0 votes against; 0 abstentions. The number of affirmative votes accounts for 100% of the valid votes
3. Documents for reference
- Resolution of the sixth meeting of the ninth board of directors;
Announcement hereby!
Board of Directors of Wuhan Haite Biopharmaceutical Co., Ltd.
December 30, 2025